报价延迟最少15分钟:2026/02/19 13:47 EST
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
2.265 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
0.37/-0.83
|
|
企业价值
147.55M
|
| 资产负债 |
|
每股账面净值
2.21
|
| 现金流量 |
|
现金流量率
0.16
|
| 损益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535. |
